1,328 Followers on Owler
Adaptimmune is a biotechnology company that researches and develops T-cell receptors for the treatment of cancer and infectious diseases...
Read moreAdaptimmune is a biotechnology company that researches and develops T-cell receptors for the treatment of cancer and infectious diseases...
Read more
News
Jan 09, 2023
FinanzNachrichten
Adaptimmune: Adaptimmune Therapeutics PLC: Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
Dec 23, 2022
FinanzNachrichten
Adaptimmune: Adaptimmune Therapeutics PLC: Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma
Dec 09, 2022
Seeking Alpha
Adaptimmune: Adaptimmune: The Afamicel Rolling BLA Is Its Lifeline
Nov 18, 2022
FinanzNachrichten
Adaptimmune: Adaptimmune Therapeutics PLC: Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent
Nov 09, 2022
PharmaLive
Adaptimmune: Adaptimmune slashes 25% of headcount despite improved data for T-cell candidate
Nov 09, 2022
Owler
Adaptimmune Therapeutics PLC: Adaptimmune's revenue changed from $11.73M in Jun 2022 to $17.54M in Sep 2022
Nov 08, 2022
Seeking Alpha
Adaptimmune: Adaptimmune GAAP EPS of -$0.04 beats by $0.22, revenue of $7M beats by $2.03M
Nov 08, 2022
BioSpace
Adaptimmune: Adaptimmune Reports Third-Quarter Financial Results and Business Update
Nov 08, 2022
FinanzNachrichten
Adaptimmune: Adaptimmune Therapeutics PLC: Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers
Oct 25, 2022
NewsFile
Press Release: Adaptimmune : Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
Adaptimmune Competitors
1
2
3
4
5
6
7
8
9
10
Looking for similar companies to Adaptimmune?
Adaptimmune Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$17.5M
Adaptimmune's revenue is the ranked 12th among it's top 10 competitors. The top 10 competitors average 30.9B. Over the last four quarters, Adaptimmune's revenue has decreased by 79.8%. Specifically, in Q4 2021's revenue was $1.4M; in Q1 2022, it was $3.6M; in Q2 2022, it was $5.5M; in Q3 2022, Adaptimmune's revenue was $7M.
Adaptimmune News
Adaptimmune Press Releases
Adaptimmune Videos
Adaptimmune Headquarters
Adaptimmune Summary
ABOUT
Overview
Adaptimmune is a biotechnology company that researches and develops T-cell receptors for the treatment of cancer and infectious diseases. Adaptimmune was founded in 2008. Adaptimmune's headquarters is located in Oxfordshire, England, GB OX14 4RX. Ada...CEO
Adaptimmune's CEO, Adrian Rawcliffe, currently has an approval rating of 91%. Adaptimmune's primary competitors are Medigene, Immatics & Immunocore.Website
adaptimmune.comCompetitors
View 16 Adaptimmune competitors here.Acquisitions
There have been no acquisitions found related to AdaptimmuneInvestments
Recent investment data cannot be found related to AdaptimmuneFrequently Asked Questions about Adaptimmune
When was Adaptimmune founded?
Adaptimmune was founded in 2008Who is Adaptimmune's CEO?
Adaptimmune's CEO is Adrian RawcliffeHow much revenue does Adaptimmune generate?
Adaptimmune generates $17.5M in revenueHow much funding does Adaptimmune have?
Adaptimmune has historically raised $458.7M in funding
Where is Adaptimmune's headquarters?
Adaptimmune's headquarters is in Oxfordshire England, GBHow many employees does Adaptimmune have?
Adaptimmune has 494 employeesWhat sector does Adaptimmune operate in?
Adaptimmune is in BiotechnologyWho are Adaptimmune's competitors?
Adaptimmune's top competitors are Medigene, Immatics, Immunocore